Evaluation of the PEG Density in the PEGylated Chitosan Nanoparticles as a Drug Carrier for Curcumin and Mitoxantrone

Yao, Chen; Wu, Di; Zhong, Wei; Kuang, Shuwen; Luo, Qian; Song, Liujiang; Feng, Xing; Tao, Xiaojun

doi:10.3390/nano8070486

Cited by 28 publications

(14 citation statements)

References 41 publications

(55 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, the ICA release increased at pH 6.8. Also, ICA release was faster than the drug release of other NPs assembled by similar conjugates consisting of nanomaterials and a drug with a chemical link [43,44]. The ICA release may be from ICA and also mPEG-ICA.…”

Section: Discussionmentioning

confidence: 94%

mPEG-icariin nanoparticles for treating myocardial ischaemia

Zheng

Yan

et al. 2019

Artificial Cells, Nanomedicine, and Biotechnology

Self Cite

View full text Add to dashboard Cite

Icariin (ICA), a major active ingredient from Chinese medicine, has unique pharmacological effects on ischaemic heart disease. However, its hydrophobic property limits its administration and leads to poor efficacy. This work aimed to change its hydrophobic property and improve the treatment efficacy. We designed a new nano-drug to increase the ICA delivery. ICA was modified with hydrophilic polyethylene glycol monomethyl ether (mPEG) by a succinic anhydride linker to form a polyethylene glycol-icariin (mPEG-ICA) polymer. The structure of this polymer was identified by Fourier transform infrared spectroscopy and nuclear magnetic resonance spectroscopy. The content of ICA in the polymer was 32% as detected by ultraviolet spectrophotometry. mPEG-ICA nanoparticles, of 143.3 nm, were prepared by the dialysis method, and zeta potential was 0.439 mV by dynamic light scattering. The nanoparticles had a spherical shape on transmission electron microscopy. In media with pH 7.4 and 6.8, ICA release from mPEG-ICA nanoparticles after 72 h was about 0.78% and 64.05%, respectively, so the ICA release depended on the release media pH. On MTT and lactate dehydrogenase activity assay, mPEG-ICA nanoparticles could reduce cell damage induced by oxgen-glucose deprivation. Hoechst 33258 staining and TUNEL and AnnexinV-FITC/PI double staining showed that ICA nanoparticles could increase the activity of H9c2 cardiomyocytes under oxgen-glucose deprivation conditions by decreasing apoptosis. ICA modified by hydrophilic mPEG could improve its efficacy.

show abstract

Section: Discussionmentioning

confidence: 94%

mPEG-icariin nanoparticles for treating myocardial ischaemia

Zheng

Yan

et al. 2019

Artificial Cells, Nanomedicine, and Biotechnology

Self Cite

View full text Add to dashboard Cite

show abstract

“…MTO release had a biphasic character; that is, the drug was released rapidly in the first 12 h, at 56.73%, 39.82%, 32.45%, and 28.02%, respectively, and the drug release rate was slowed down within 12 to 48 h, with cumulative release percentages of 68.75%, 50.54%, 35.22%, and 31.68%, respectively. Because NPs capture hydrophobic drugs in two forms of loading, surface adsorption, and core loading, the surfaceadsorbed drug was rapidly released, whereas the core-loaded drug was slowly and continuously released [38]. The drug release of the NPs complexed with HSA was much slower.…”

Section: Changes In Secondary Structure With Drug-loaded Chpmentioning

confidence: 99%

Interaction of Mitoxantrone-Loaded Cholesterol Modified Pullulan Nanoparticles with Human Serum Albumin and Effect on Drug Release

Yuan

Guo

Zhong

et al. 2019

Journal of Nanomaterials

Self Cite

View full text Add to dashboard Cite

To clarify nanoparticle-protein interaction and their action characteristics, the interactions between MTO-CHP NPs and human serum albumin (HSA) were studied by isothermal titration calorimetry (ITC), fluorescence spectroscopy, dynamic light scattering (DLS), and circular dichroism spectroscopy (CD). Hydrophobically modified pullulan (CHP) nanoparticles (NPs) loaded with mitoxantrone (MTO) were prepared (MTO-CHP NPs) with size 166.9 nm. The spherical shape was verified by transmission electron microscopy (TEM). The ITC results demonstrated an interaction between MTO-CHP NPs mainly by hydrophobic interaction force, electrostatic force, and hydrogen bonding. The mean binding constant KA was 0.832×104 M−1 and mean HSA coverage 0.939±0.302. MTO-CHP NPs could quench the fluorescence intensity of HSA, which gradually decreased to be balanced in 9 h and indicated the completion of the complexation. The size and zeta potential changes of the combined particle were dynamically detected with DLS at 0, 3, 6, 9, 12, 15, and 18 h. When the reaction was completed at 9 h, the particle size and potential remained stable, accompanied by a size change from 89.91 to about 145 nm and potential change from -15 to -3 mV, respectively. The results of CD measurement showed that the change in ellipticity of HSA at 208 nm was similar to the fluorescence spectra and DLS measurements with MTO-CHP NPs combined with HSA. At the beginning of the reaction, the proportion of α-helix was 52.3% to 43.7%, which decreased by 39.1% at compound stabilization. The release of MTO from MTO-CHP NPs at pH=5.6 was significantly accelerated, whereas that of MTO from HSA-MTO-CHP NPs was significantly reduced, and the drug release was significantly slowed down even under acidic conditions, which indicates the beneficial effect of HSA on the persistence and stability of the HSA-MTO-CHP NP compound.

show abstract

“…GCS is a chitosan derivative with an ethylene glycol group, replacing specific polysaccharide repeating units with a hydroxyl group for better hydrophilicity [ 65 ]. Reduced clearance (escaped phagocytosis of RES cells) will increase drug circulation time, tumor aggregation, and toxicity [ 79 , 80 ].…”

Section: Chitosan-based Systems As Drug Carriers In Targetted Drug Delivery Systems In Bc Treatmentmentioning

confidence: 99%

Chitosan-Based Nanoparticles of Targeted Drug Delivery System in Breast Cancer Treatment

et al. 2021

View full text Add to dashboard Cite

Breast cancer remains one of the world’s most dangerous diseases because of the difficulty of finding cost-effective and specific targets for effective and efficient treatment methods. The biodegradability and biocompatibility properties of chitosan-based nanoparticles (ChNPs) have good prospects for targeted drug delivery systems. ChNPs can transfer various antitumor drugs to targeted sites via passive and active targeting pathways. The modification of ChNPs has attracted the researcher to the loading of drugs to targeted cancer cells. The objective of our review was to summarize and discuss the modification in ChNPs in delivering anticancer drugs against breast cancer cells from published papers recorded in Scopus, PubMed, and Google Scholar. In order to improve cellular uptake, drug accumulation, cytotoxicity, and selectivity, we examined different kinds of modification of ChNPs. Notably, these forms of ChNPs use the characteristics of the enhanced permeability and retention (EPR) effect as a proper parameter and different biological ligands, such as proteins, peptides, monoclonal antibodies, and small particles. In addition, as a targeted delivery system, ChNPs provided and significantly improved the delivery of drugs into specific breast cancer cells (MDA-MB-231, 4T1 cells, SK-BR-3, MCF-7, T47D). In conclusion, a promising technique is presented for increasing the efficacy, selectivity, and effectiveness of candidate drug carriers in the treatment of breast cancer.

show abstract

Evaluation of the PEG Density in the PEGylated Chitosan Nanoparticles as a Drug Carrier for Curcumin and Mitoxantrone

Cited by 28 publications

References 41 publications

mPEG-icariin nanoparticles for treating myocardial ischaemia

mPEG-icariin nanoparticles for treating myocardial ischaemia

Interaction of Mitoxantrone-Loaded Cholesterol Modified Pullulan Nanoparticles with Human Serum Albumin and Effect on Drug Release

Chitosan-Based Nanoparticles of Targeted Drug Delivery System in Breast Cancer Treatment

Contact Info

Product

Resources

About